The PD-1/PD-L1 signaling pathway represents the most studied immune checkpoint for cancer immunotherapy, and restoring T cell-mediated adaptive immunity has become one of the most frequently used strategies [51, 74]. The gene discussed is PDCD1; the disease is cancer.